The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Sclerostin Antibody Treatment Increases Bone Formation, Bone Mass, and Bone Strength in a Rat Model of Postmenopausal Osteoporosis
Abstract
The development of bone-rebuilding anabolic agents for potential use in the treatment of bone loss conditions, such as osteoporosis, has been a long-standing goal. Genetic studies in humans and mice have shown that the secreted protein sclerostin is a key negative regulator of bone formation, although the magnitude and extent of sclerostin's role in the control of bone formation in the aging skeleton is still unclear. To study this unexplored area of sclerostin biology and to assess the pharmacologic effects of sclerostin inhibition, we used a cell culture model of bone formation to identify a sclerostin neutralizing monoclonal antibody (Scl-AbII) for testing in an aged ovariectomized rat model of postmenopausal osteoporosis. Six-month-old female rats were ovariectomized and left untreated for 1 yr to allow for significant estrogen deficiency-induced bone loss, at which point Scl-AbII was administered for 5 wk. Scl-AbII treatment in these animals had robust anabolic effects, with marked increases in bone formation on trabecular, periosteal, endocortical, and intracortical surfaces. This not only resulted in complete reversal, at several skeletal sites, of the 1 yr of estrogen deficiency-induced bone loss, but also further increased bone mass and bone strength to levels greater than those found in non-ovariectomized control rats. Taken together, these preclinical results establish sclerostin's role as a pivotal negative regulator of bone formation in the aging skeleton and, furthermore, suggest that antibody-mediated inhibition of sclerostin represents a promising new therapeutic approach for the anabolic treatment of bone-related disorders, such as postmenopausal osteoporosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Parfitt, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. A., Malluche, H., Meunier, P. J., Ott, S. M., & Recker, R. R. (1987) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650020617 · Cited by 5,016
Bone Histomorphometry : Standardization of Nomenclature, Symbols, and Units
PARFITT, A. M., Drezner, M. K., Glorieux, F. H., Kanis, J. А., Malluche, H. H., Meunier, P. J., Ott, S. M., & Recker, R. R. (1987) · Journal of Bone and Mineral Research · Cited by 3,258
Sudo, H., Kodama, H. A., Amagai, Y., Yamamoto, S., & Kasai, S. (1983) · The Journal of cell biology · doi:10.1083/jcb.96.1.191 · Cited by 1,671
Sclerostin Binds to LRP5/6 and Antagonizes Canonical Wnt Signaling
Li, X., Zhang, Y., Kang, H., Liu, W., Liu, P., Zhang, J., Harris, S. E., & Wu, D. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413274200 · Cited by 1,366
Self-citationThe ovariectomized rat model of postmenopausal bone loss
Kalu, D. N. (1991) · Bone and Mineral · doi:10.1016/0169-6009(91)90124-i · Cited by 1,361
Wnt Signaling: Multiple Pathways, Multiple Receptors, and Multiple Transcription Factors
Gordon, M. D., & Nusse, R. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.r600015200 · Cited by 1,333
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
Balemans, W. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.5.537 · Cited by 1,147
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist
Winkler, D. G. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg599 · Cited by 1,112
Brunkow, M. E., Gardner, J. C., Van Ness, J., Paeper, B. W., Kovacevich, B. R., Proll, S., Skonier, J. E., Zhao, L., Sabo, P. J., Fu, Y.-H., et al. (2001) · The American Journal of Human Genetics · doi:10.1086/318811 · Cited by 1,011
Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation
Poole, K. E. S., Van Bezooijen, R. L., Loveridge, N., Hamersma, H., Papapoulos, S. E., Löwik, C. W., & Reeve, J. (2005) · The FASEB Journal · doi:10.1096/fj.05-4221fje · Cited by 965
Cited by
Osteoporosis: now and the future
Rachner, T. D., Khosla, S., & Hofbauer, L. C. (2011) · The Lancet · doi:10.1016/s0140-6736(10)62349-5 · Cited by 2,696
WNT signaling in bone homeostasis and disease: From human mutations to treatments
Baron, R., & Kneissel, M. (2013) · Nature Medicine · doi:10.1038/nm.3074 · Cited by 2,093
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
McClung, M. R., Grauer, A., Boonen, S., Bolognese, M. A., Brown, J. P., Diez-Perez, A., Langdahl, B. L., Reginster, J.-Y., Zanchetta, J. R., Wasserman, S. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1305224 · Cited by 1,258
Can we safely target the WNT pathway?
Kahn, M. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4233 · Cited by 1,034
Inflammatory bone loss: pathogenesis and therapeutic intervention
Redlich, K., & Smolen, J. S. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3669 · Cited by 830
Prevention and treatment of postmenopausal osteoporosis
Tella, S. H., & Gallagher, J. C. (2014) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2013.09.008 · Cited by 786
Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody
Padhi, D., Jang, G., Stouch, B., Fang, L., & Posvar, E. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.173 · Cited by 786
Osteoclast differentiation by RANKL and OPG signaling pathways
Udagawa, N., Koide, M., Nakamura, M., Nakamichi, Y., Yamashita, T., Uehara, S., Kobayashi, Y., Furuya, Y., Yasuda, H., Fukuda, C., et al. (2021) · Journal of Bone and Mineral Metabolism · doi:10.1007/s00774-020-01162-6 · Cited by 708
Irisin Mediates Effects on Bone and Fat via αV Integrin Receptors
Kim, H., Wrann, C. D., Jedrychowski, M., Vidoni, S., Kitase, Y., Nagano, K., Zhou, C., Chou, J., Parkman, V.-J. A., Novick, S. J., et al. (2018) · Cell · doi:10.1016/j.cell.2018.10.025 · Cited by 638
“, 2017) and as such these cells have become a prime target for anabolic osteoporotic therapies such as parathyroid hormone and monoclonal anti-sclerostin antibodies (Bellido et al., 2005; Keller and Kneissel, 2005; Li et al., 2009; Ominsky et al., 2010).”
Aging and bone loss: new insights for the clinician
Demontiero, O., Vidal, C., & Duque, G. (2012) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x11430858 · Cited by 559
Parathyroid hormone: anabolic and catabolic actions on the skeleton
Silva, B. C., & Bilezikian, J. P. (2015) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2015.03.005 · Cited by 557
Osteocytes: master orchestrators of bone
Schaffler, M. B., Cheung, W.-Y., Majeska, R., & Kennedy, O. (2014) · Calcified Tissue International · doi:10.1007/s00223-013-9790-y · Cited by 514
Sclerostin Stimulates Osteocyte Support of Osteoclast Activity by a RANKL-Dependent Pathway
Wijenayaka, A. R., Kogawa, M., Lim, H. P., Bonewald, L. F., Findlay, D. M., & Atkins, G. J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0025900 · Cited by 503
Crockett, J. C., Rogers, M. J., Coxon, F. P., Hocking, L. J., & Helfrich, M. H. (2011) · Journal of Cell Science · doi:10.1242/jcs.063032 · Cited by 500
Ominsky, M. S., Vlasseros, F., Jolette, J., Smith, S. Y., Stouch, B., Doellgast, G., Gong, J., Gao, Y., Cao, J., Graham, K., et al. (2010) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.14 · Cited by 414
Self-citationSclerostin and Dickkopf-1 as Therapeutic Targets in Bone Diseases
Ke, H. Z., Richards, W. G., Li, X., & Ominsky, M. S. (2012) · Endocrine Reviews · doi:10.1210/er.2011-1060 · Cited by 402
Self-citationRelation of age, gender, and bone mass to circulating sclerostin levels in women and men
Mödder, U. I., Hoey, K. A., Amin, S., McCready, L. K., Achenbach, S. J., Riggs, B. L., Melton, L. J., & Khosla, S. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.217 · Cited by 397
Update on Wnt signaling in bone cell biology and bone disease
Monroe, D. G., McGee-Lawrence, M. E., Oursler, M. J., & Westendorf, J. J. (2012) · Gene · doi:10.1016/j.gene.2011.10.044 · Cited by 392
Wnt signaling in bone formation and its therapeutic potential for bone diseases
Kim, J. H., Liu, X., Wang, J., Chen, X., Zhang, H., Kim, S. H., Cui, J., Li, R., Zhang, W., Kong, Y., et al. (2013) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x12466608 · Cited by 356
The Regulation of Bone Metabolism and Disorders by Wnt Signaling
Maeda, K., Kobayashi, Y., Koide, M., Uehara, S., Okamoto, M., Ishihara, A., Kayama, T., Saito, M., & Marumo, K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225525 · Cited by 353
Strontium signaling: Molecular mechanisms and therapeutic implications in osteoporosis
Saidak, Z., & Marie, P. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.07.009 · Cited by 334
Sclerostin: Current Knowledge and Future Perspectives
Moester, M. J. C., Papapoulos, S. E., Löwik, C. W. G. M., & van Bezooijen, R. L. (2010) · Calcified Tissue International · doi:10.1007/s00223-010-9372-1 · Cited by 332
Mechanisms of bone repair and regeneration
Deschaseaux, F., Sensébé, L., & Heymann, D. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.07.002 · Cited by 324
Update on Bone Anabolics in Osteoporosis Treatment: Rationale, Current Status, and Perspectives
Baron, R., & Hesse, E. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2332 · Cited by 320
Circulating Levels of Sclerostin Are Increased in Patients with Type 2 Diabetes Mellitus
García-Martín, A., Rozas-Moreno, P., Reyes-García, R., Morales-Santana, S., García-Fontana, B., García-Salcedo, J. A., & Muñoz-Torres, M. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2186 · Cited by 311
Mirza, F. S., Padhi, I. D., Raisz, L. G., & Lorenzo, J. A. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2283 · Cited by 311
Wnt signalling in osteoporosis: mechanisms and novel therapeutic approaches
Canalis, E. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.154 · Cited by 304
Walker, E. C., McGregor, N. E., Poulton, I. J., Solano, M., Pompolo, S., Fernandes, T. J., Constable, M. J., Nicholson, G. C., Zhang, J.-G., Nicola, N. A., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci40568 · Cited by 300
Local communication on and within bone controls bone remodeling
Henriksen, K., Neutzsky-Wulff, A. V., Bonewald, L. F., & Karsdal, M. A. (2009) · Bone · doi:10.1016/j.bone.2009.03.671 · Cited by 282
Amrein, K., Amrein, S., Drexler, C., Dimai, H. P., Dobnig, H., Pfeifer, K., Tomaschitz, A., Pieber, T. R., & Fahrleitner-Pammer, A. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2152 · Cited by 277
Osteocyte: the unrecognized side of bone tissue
Rochefort, G. Y., Pallu, S., & Benhamou, C. L. (2010) · Osteoporosis International · doi:10.1007/s00198-010-1194-5 · Cited by 268
Skeletal Aging and Osteoporosis: Mechanisms and Therapeutics
Chandra, A., & Rajawat, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073553 · Cited by 264
Ominsky, M. S., Li, C., Li, X., Tan, H. L., Lee, E., Barrero, M., Asuncion, F. J., Dwyer, D., Han, C.-Y., Vlasseros, F., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.307 · Cited by 264
Self-citationA bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair
Florio, M., Gunasekaran, K., Stolina, M., Li, X., Liu, L., Tipton, B., Salimi-Moosavi, H., Asuncion, F. J., Li, C., Sun, B., et al. (2016) · Nature Communications · doi:10.1038/ncomms11505 · Cited by 257
Self-citationWoo, S. M., Rosser, J., Dusevich, V., Kalajzic, I., & Bonewald, L. F. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.465 · Cited by 243
Osteoblasts in osteoporosis: Past, emerging, and future anabolic targets
Marie, P. J., & Kassem, M. (2011) · European Journal of Endocrinology · doi:10.1530/eje-11-0132 · Cited by 234
The WNT system: background and its role in bone
Lerner, U. H., & Ohlsson, C. (2015) · Journal of Internal Medicine · doi:10.1111/joim.12368 · Cited by 228
Ma, X., Meng, J., Jia, M., Bi, L., Zhou, Y., Wang, Y., Hu, J., He, G., & Luo, X. (2013) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.1898 · Cited by 200
“However, among therapeutics currently used to treat osteoporosis, the vast majority are antiresorptive agents, which exert their clinical effect by decreasing the rate of bone resorption, thereby preventing further bone loss and achieving a reduction in fracture incidence.((2,3)) A significant unmet need remains for a…”
BackgroundOminsky, M. S., Niu, Q.-T., Li, C., Li, X., & Ke, H. Z. (2014) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.2152 · Cited by 167
Self-citationRomosozumab for the treatment of osteoporosis
Bandeira, L., Lewiecki, E. M., & Bilezikian, J. P. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1280455 · Cited by 101
Targeting WNT signaling in the treatment of osteoporosis
Baron, R., & Gori, F. (2018) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2018.04.011 · Cited by 101
Update in new anabolic therapies for osteoporosis
Canalis, E. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2677 · Cited by 85
Stein, M., Elefteriou, F., Busse, B., Fiedler, I. A., Kwon, R. Y., Farrell, E., Ahmad, M., Ignatius, A., Grover, L., Geris, L., et al. (2023) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.4868 · Cited by 42
Future directions for new medical entities in osteoporosis
Ferrari, S. (2014) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2014.08.002 · Cited by 34
Silverman, S. L. (2010) · Journal of Osteoporosis · doi:10.4061/2010/941419 · Cited by 30
Metadata
- Authors
- Li, X., Ominsky, M. S., Warmington, K. S., Morony, S., Gong, J., Cao, J., Gao, Y., Shalhoub, V., Tipton, B., Haldankar, R., Chen, Q., Winters, A., Boone, T., Geng, Z., Niu, Q.-T., Ke, H. Z., Kostenuik, P. J., Simonet, W. S., Lacey, D. L., & Paszty, C.
- Venue
- Journal of Bone and Mineral Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2009-04-01
- Volume
- 24
- Issue
- 4
- Pages
- 578-588
- ISSN
- 0884-0431 (ISSN-L)
- 1523-4681
- OpenAlex
- W1983220846
- Cited by
- 784
- References
- 40
- FWCI
- 46.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.